← All trials
NCT00905983
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2007
- Primary completion
- Sep 1, 2009
- Completion date
- Sep 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 48
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Hospital Universitario Arnau de Vilanova de LleidaLead sponsor
- Fundación Althaia ManresaOverall official - principal investigator
- University of ValenciaOverall official - principal investigator
- H. Universitario Dr. PesetOverall official - principal investigator
- Hospital General de EldaOverall official - principal investigator
- Hospital de SaguntoOverall official - principal investigator
- University AlicanteOverall official - principal investigator
- Hospital General Universitario de CastellónOverall official - principal investigator
- Hospital Virgen de los LiriosOverall official - principal investigator
- University of ValenciaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.